Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stock
Expecting a further pickup in Emcure Pharmaceuticals’ organic growth in 2HFY25, domestic brokerage firm Kotak Institutional Equities upgraded the stock’s rating to ‘buy’ from an ‘add’ earlier, with a target …